540 related articles for article (PubMed ID: 23102796)
1. Activities of doripenem against nosocomial bacteremic drug-resistant Gram-negative bacteria in a medical center in Taiwan.
Dong SX; Wang JT; Chang SC
J Microbiol Immunol Infect; 2012 Dec; 45(6):459-64. PubMed ID: 23102796
[TBL] [Abstract][Full Text] [Related]
2. Comparative Activity of Carbapenem Testing (COMPACT) study in Germany.
Valenza G; Seifert H; Decker-Burgard S; Laeuffer J; Morrissey I; Mutters R;
Int J Antimicrob Agents; 2012 Mar; 39(3):255-8. PubMed ID: 22230334
[TBL] [Abstract][Full Text] [Related]
3. Longitudinal survey of carbapenem resistance and resistance mechanisms in Enterobacteriaceae and non-fermenters from the USA in 2007-09.
Davies TA; Marie Queenan A; Morrow BJ; Shang W; Amsler K; He W; Lynch AS; Pillar C; Flamm RK
J Antimicrob Chemother; 2011 Oct; 66(10):2298-307. PubMed ID: 21775338
[TBL] [Abstract][Full Text] [Related]
4. Carbapenem susceptibilities and non-susceptibility concordance to different carbapenems amongst clinically important Gram-negative bacteria isolated from intensive care units in Taiwan: results from the Surveillance of Multicentre Antimicrobial Resistance in Taiwan (SMART) in 2009.
Jean SS; Hsueh PR; Lee WS; Yu KW; Liao CH; Chang FY; Ko WC; Wu JJ; Chen YH; Chen YS; Liu JW; Lu MC; Liu CY; Lam C; Chen RJ
Int J Antimicrob Agents; 2013 May; 41(5):457-62. PubMed ID: 23507415
[TBL] [Abstract][Full Text] [Related]
5. Comparative in vitro activity of carbapenems against major Gram-negative pathogens: results of Asia-Pacific surveillance from the COMPACT II study.
Kiratisin P; Chongthaleong A; Tan TY; Lagamayo E; Roberts S; Garcia J; Davies T
Int J Antimicrob Agents; 2012 Apr; 39(4):311-6. PubMed ID: 22386743
[TBL] [Abstract][Full Text] [Related]
6. [Comparative evaluation of in vitro activities of carbapenems against gram-negative pathogens: Turkish data of COMPACT study].
Korten V; Söyletir G; Yalçın AN; Oğünç D; Dokuzoğuz B; Esener H; Ulusoy S; Tünger A; Aygen B; Sümerkan B; Arman D; Dizbay M; Akova M; Hasçelik G; Eraksoy H; Başaran S; Köksal I; Bayramoğlu G; Akalın H; Sınırtaş M
Mikrobiyol Bul; 2011 Apr; 45(2):197-209. PubMed ID: 21644063
[TBL] [Abstract][Full Text] [Related]
7. Pharmacodynamic profiling of doripenem, imipenem and meropenem against prevalent Gram-negative organisms in the Asia-Pacific region.
Kiratisin P; Keel RA; Nicolau DP
Int J Antimicrob Agents; 2013 Jan; 41(1):47-51. PubMed ID: 23127484
[TBL] [Abstract][Full Text] [Related]
8. Antimicrobial susceptibility of pathogens isolated from patients with complicated intra-abdominal infections at five medical centers in Taiwan that continuously participated in the Study for Monitoring Antimicrobial Resistance Trends (SMART) from 2006 to 2010.
Lee YL; Chen YS; Toh HS; Huang CC; Liu YM; Ho CM; Lu PL; Ko WC; Chen YH; Wang JH; Tang HJ; Yu KW; Liu YC; Chuang YC; Liu CE; Hsueh PR
Int J Antimicrob Agents; 2012 Jun; 40 Suppl():S29-36. PubMed ID: 22749056
[TBL] [Abstract][Full Text] [Related]
9. Antimicrobial activity of doripenem and other carbapenems against gram-negative pathogens from Korea.
Lee H; Ko KS; Song JH; Peck KR
Microb Drug Resist; 2011 Mar; 17(1):37-45. PubMed ID: 20950191
[TBL] [Abstract][Full Text] [Related]
10. Antimicrobial susceptibility patterns of multidrug-resistant Pseudomonas aeruginosa and Acinetobacter baumannii against carbapenems, colistin, and tigecycline.
Somily AM; Absar MM; Arshad MZ; Al Aska AI; Shakoor ZA; Fatani AJ; Siddiqui YM; Murray TS
Saudi Med J; 2012 Jul; 33(7):750-5. PubMed ID: 22821309
[TBL] [Abstract][Full Text] [Related]
11. Predictability of doripenem susceptibility in Acinetobacter baumannii isolates based on other carbapenem susceptibilities and bla OXA gene status.
Esterly JS; Qi C; Malczynski M; Scheetz MH
Pharmacotherapy; 2010 Apr; 30(4):354-60. PubMed ID: 20334455
[TBL] [Abstract][Full Text] [Related]
12. Assessing the pharmacodynamic profile of intravenous antibiotics against prevalent Gram-negative organisms collected in Colombia.
Villegas MV; Briceno DF; Ruiz SJ; Furtado GH; Nicolau DP
Braz J Infect Dis; 2011; 15(5):413-9. PubMed ID: 22230846
[TBL] [Abstract][Full Text] [Related]
13. Comparison of in vitro activity of doripenem, imipenem and meropenem against clinical isolates of Enterobacteriaceae, Pseudomonas and Acinetobacter in Southern Poland.
Drzewiecki A; Bulanda M; Talaga K; Sodo A; Adamski P
Pol Przegl Chir; 2012 Sep; 84(9):449-53. PubMed ID: 23241660
[TBL] [Abstract][Full Text] [Related]
14. Pharmacodynamic profiling of intravenous antibiotics against prevalent Gram-negative organisms across the globe: the PASSPORT Program-Asia-Pacific Region.
Roberts JA; Kwa A; Montakantikul P; Gomersall C; Kuti JL; Nicolau DP
Int J Antimicrob Agents; 2011 Mar; 37(3):225-9. PubMed ID: 21168997
[TBL] [Abstract][Full Text] [Related]
15. Carbapenem-resistant Gram-negative bacilli in Canada 2009-10: results from the Canadian Nosocomial Infection Surveillance Program (CNISP).
Mataseje LF; Bryce E; Roscoe D; Boyd DA; Embree J; Gravel D; Katz K; Kibsey P; Kuhn M; Mounchili A; Simor A; Taylor G; Thomas E; Turgeon N; Mulvey MR;
J Antimicrob Chemother; 2012 Jun; 67(6):1359-67. PubMed ID: 22398651
[TBL] [Abstract][Full Text] [Related]
16. In vitro activity of isepamicin and other aminoglycosides against clinical isolates of Gram-negative bacteria causing nosocomial bloodstream infections.
Tsai TY; Chang SC; Hsueh PR; Feng NH; Wang JT
J Microbiol Immunol Infect; 2007 Dec; 40(6):481-6. PubMed ID: 18087627
[TBL] [Abstract][Full Text] [Related]
17. Doripenem vs meropenem against Pseudomonas and Acinetobacter.
Goyal K; Gautam V; Ray P
Indian J Med Microbiol; 2012; 30(3):350-1. PubMed ID: 22885206
[TBL] [Abstract][Full Text] [Related]
18. Combined effects of the siderophore monosulfactam BAL30072 and carbapenems on multidrug-resistant Gram-negative bacilli.
Hofer B; Dantier C; Gebhardt K; Desarbre E; Schmitt-Hoffmann A; Page MG
J Antimicrob Chemother; 2013 May; 68(5):1120-9. PubMed ID: 23344577
[TBL] [Abstract][Full Text] [Related]
19. In vitro activity of doripenem and other carbapenems against contemporary Gram-negative pathogens isolated from hospitalised patients in the Asia-Pacific region: results of the COMPACT Asia-Pacific Study.
Christiansen KJ; Ip M; Ker HB; Mendoza M; Hsu L; Kiratisin P; Chongthaleong A; Redjeki IS; Quintana A; Flamm R; Garcia J; Cassettari M; Cooper D; Okolo P; Morrissey I
Int J Antimicrob Agents; 2010 Dec; 36(6):501-6. PubMed ID: 20869212
[TBL] [Abstract][Full Text] [Related]
20. Comparative in vitro antimicrobial susceptibilities and synergistic activities of antimicrobial combinations against carbapenem-resistant Acinetobacter species: Acinetobacter baumannii versus Acinetobacter genospecies 3 and 13TU.
Sheng WH; Wang JT; Li SY; Lin YC; Cheng A; Chen YC; Chang SC
Diagn Microbiol Infect Dis; 2011 Jul; 70(3):380-6. PubMed ID: 21558048
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
